Free Trial

Emergent Biosolutions (EBS) Competitors

Emergent Biosolutions logo
$6.94 -0.34 (-4.67%)
Closing price 03:59 PM Eastern
Extended Trading
$6.94 +0.00 (+0.07%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EBS vs. JNJ, CLDX, DVAX, INVA, MNKD, NVAX, OPK, GERN, RGLS, and ZBIO

Should you be buying Emergent Biosolutions stock or one of its competitors? The main competitors of Emergent Biosolutions include Johnson & Johnson (JNJ), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), and Zenas BioPharma (ZBIO). These companies are all part of the "medical" sector.

Emergent Biosolutions vs. Its Competitors

Emergent Biosolutions (NYSE:EBS) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

In the previous week, Johnson & Johnson had 157 more articles in the media than Emergent Biosolutions. MarketBeat recorded 159 mentions for Johnson & Johnson and 2 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.14 beat Emergent Biosolutions' score of 0.53 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Emergent Biosolutions
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Johnson & Johnson
104 Very Positive mention(s)
12 Positive mention(s)
22 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Positive

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 1.2% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Emergent Biosolutions currently has a consensus price target of $14.33, indicating a potential upside of 106.53%. Johnson & Johnson has a consensus price target of $172.87, indicating a potential upside of 5.63%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, equities research analysts plainly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Emergent Biosolutions
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Johnson & Johnson
0 Sell rating(s)
11 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.57

Emergent Biosolutions has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Johnson & Johnson has a net margin of 25.00% compared to Emergent Biosolutions' net margin of -13.63%. Johnson & Johnson's return on equity of 33.07% beat Emergent Biosolutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Emergent Biosolutions-13.63% -0.52% -0.17%
Johnson & Johnson 25.00%33.07%13.16%

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent Biosolutions$1.04B0.36-$190.60M-$2.71-2.56
Johnson & Johnson$88.82B4.43$14.07B$9.3517.50

Summary

Johnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EBS vs. The Competition

MetricEmergent BiosolutionsMED IndustryMedical SectorNYSE Exchange
Market Cap$395.14M$2.91B$5.52B$20.73B
Dividend YieldN/A2.45%3.80%3.69%
P/E Ratio-2.5619.8828.0427.57
Price / Sales0.36305.11429.5359.01
Price / Cash3.7943.1635.8422.13
Price / Book0.787.678.124.66
Net Income-$190.60M-$55.28M$3.25B$994.58M
7 Day Performance-5.45%2.50%0.97%-0.29%
1 Month Performance10.04%11.70%7.36%4.91%
1 Year Performance-39.28%4.89%31.31%10.53%

Emergent Biosolutions Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EBS
Emergent Biosolutions
4.1458 of 5 stars
$6.94
-4.7%
$14.33
+106.5%
-39.4%$395.14M$1.04B-2.562,420
JNJ
Johnson & Johnson
4.7823 of 5 stars
$156.91
+0.0%
$171.00
+9.0%
+4.1%$377.55B$89.33B17.45138,100Trending News
Earnings Report
Dividend Announcement
Analyst Forecast
Options Volume
Analyst Revision
CLDX
Celldex Therapeutics
2.4484 of 5 stars
$23.36
+2.0%
$50.11
+114.5%
-40.8%$1.55B$7.02M-8.65150Positive News
DVAX
Dynavax Technologies
4.3821 of 5 stars
$10.74
+1.5%
$24.00
+123.5%
+0.0%$1.29B$294.62M-20.65350
INVA
Innoviva
4.0829 of 5 stars
$19.58
+4.3%
$40.33
+106.0%
+13.9%$1.23B$358.71M-19.39100Analyst Revision
Gap Up
MNKD
MannKind
2.6384 of 5 stars
$4.03
+6.9%
$10.33
+156.4%
-32.8%$1.22B$285.50M40.30400News Coverage
Analyst Upgrade
Insider Trade
Analyst Revision
NVAX
Novavax
4.3379 of 5 stars
$6.97
+1.9%
$17.00
+143.9%
-55.8%$1.13B$1.21B2.631,990
OPK
OPKO Health
4.0156 of 5 stars
$1.34
-0.7%
$2.75
+105.2%
-2.8%$1.06B$713.10M-19.142,997Positive News
GERN
Geron
3.46 of 5 stars
$1.34
+1.5%
$4.61
+244.1%
-72.9%$853.47M$116.29M-6.3870News Coverage
RGLS
Regulus Therapeutics
1.6644 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
ZBIO
Zenas BioPharma
1.5936 of 5 stars
$12.82
+14.7%
$36.67
+186.0%
N/A$536.26M$5M-3.61N/A

Related Companies and Tools


This page (NYSE:EBS) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners